Abstract
Results A total of 20031 ovarian cancer patients were included, with 291 (1.45%) patients who received radiotherapy. The median overall survival (OS) in patients who received radiotherapy was shorter than which in patients without radiotherapy (23 vs. 75 months, P < 0.001). The Elderly, nonepithelial pathology, advanced American Joint Committee on Cancer (AJCC) stage, elevated level of CA125, and receiving radiotherapy were risk predictors to survival in both multivariable analyses before and after PSM. Among 11872 patients with III/IV stage, the radiotherapy group also showed a significantly worse prognosis (median OS: 19 vs. 44 months in patients without radiotherapy, P < 0.001). Consistent results were observed in stratification analyses on pathology and stage among patients with III/IV stage. Conclusions For patients with ovarian cancer, radiotherapy was associated with a poor prognosis regardless of pathology or stage. Considering this is a retrospective study, future studies concerning radiotherapy combination with other new agents in ovarian cancer are needed.
Highlights
Ovarian cancer (OC), the third most common cause of death in gynecologic cancer, ranked eighth for both cancer incidence and mortality among females in 2018, with 295,414 new cancer cases and 184,799 cancer deaths in 185 countries [1]. e prognoses of OC remain diverse according to pathological type, stage at the first diagnosis, and response to treatment strategy
Treatments included surgery, chemotherapy, and radiotherapy. e primary endpoint was overall survival (OS) and the second endpoint was cause specific survival (CSS). e OS was defined as the time interval from first diagnosed as OC to death due to any cause. e CSS was defined as the time interval from diagnosis of OC to OC-related death
Patients with nonepithelial pathology type (52.92% vs. 22.88%, P < 0.001), distant stage (67.70% vs. 55.91%, P < 0.001), and III/IV stage (50.17% vs. 19.07%, P < 0.001) were more likely to receive RT. 99.82% of patients without RT received surgery of primary site, while only 67.70% of patients with RT had operations (P < 0.001)
Summary
Ovarian cancer (OC), the third most common cause of death in gynecologic cancer, ranked eighth for both cancer incidence and mortality among females in 2018, with 295,414 new cancer cases and 184,799 cancer deaths in 185 countries [1]. e prognoses of OC remain diverse according to pathological type, stage at the first diagnosis, and response to treatment strategy. A large sample size study on survival analysis of radiotherapy in ovarian cancer is deficient. Is study aimed to explore the survival impact of radiotherapy in ovarian cancer. Data of patients diagnosed with ovarian cancer between 2010 and 2015 were collected from Surveillance, Epidemiology, and End Results (SEER) Database. E Elderly, nonepithelial pathology, advanced American Joint Committee on Cancer (AJCC) stage, elevated level of CA125, and receiving radiotherapy were risk predictors to survival in both multivariable analyses before and after PSM. For patients with ovarian cancer, radiotherapy was associated with a poor prognosis regardless of pathology or stage. Considering this is a retrospective study, future studies concerning radiotherapy combination with other new agents in ovarian cancer are needed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
